| Robin Kerr, APN | |
|
1215 Sidney St Ste 300, Batesville, AR 72501-7201 | |
| (870) 793-1126 | |
| (870) 793-1180 |
| Full Name | Robin Kerr |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 15 Years |
| Location | 1215 Sidney St Ste 300, Batesville, Arkansas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083931331 | NPI | - | NPPES |
| 184896758 | Medicaid | AR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | A03370 (Arkansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| White River Medical Center | Batesville, AR | Hospital |
| Baxter Regional Medical Center | Mountain home, AR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| White River Health System Inc | 0143134270 | 150 |
News Archive
Researchers at the Mayo Clinic campus in Florida have found a clue as to how some people develop a form of dementia that affects the brain areas associated with personality, behavior, and language.
That micro-organisms have a great capacity to vary their surface structure is well known. It is one of the reasons why it is so difficult to develop vaccines against HIV and malaria, and why new influenza vaccines have to be produced every year. But it seems that these micro-organisms are also able to completely avoid activating a strong immune response in the person attacked.
Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development of first-in-class, targeted oncolytic products for cancer, today reported positive interim data from a pilot trial using JX-594 followed by sorafenib (Nexavar®) to treat liver cancer patients. The data were presented today at the Fourth Annual International Liver Cancer Association Conference in Montreal, Canada.
Acorda Therapeutics, Inc. today announced that four new analyses of clinical trial data on AMPYRA™ (dalfampridine) Extended Release Tablets 10 mg are being presented at the 62nd American Academy of Neurology Annual meeting.
One of the most important and anxiety-producing concerns among patients with lupus is whether it is safe to become pregnant. A pioneering study led by researchers at Hospital for Special Surgery has shown that most women can expect a good pregnancy outcome if their lupus is inactive and they are free of certain risk factors.
› Verified 4 days ago
| Entity Name | White River Health System Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568432144 PECOS PAC ID: 0143134270 Enrollment ID: O20040830000837 |
News Archive
Researchers at the Mayo Clinic campus in Florida have found a clue as to how some people develop a form of dementia that affects the brain areas associated with personality, behavior, and language.
That micro-organisms have a great capacity to vary their surface structure is well known. It is one of the reasons why it is so difficult to develop vaccines against HIV and malaria, and why new influenza vaccines have to be produced every year. But it seems that these micro-organisms are also able to completely avoid activating a strong immune response in the person attacked.
Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development of first-in-class, targeted oncolytic products for cancer, today reported positive interim data from a pilot trial using JX-594 followed by sorafenib (Nexavar®) to treat liver cancer patients. The data were presented today at the Fourth Annual International Liver Cancer Association Conference in Montreal, Canada.
Acorda Therapeutics, Inc. today announced that four new analyses of clinical trial data on AMPYRA™ (dalfampridine) Extended Release Tablets 10 mg are being presented at the 62nd American Academy of Neurology Annual meeting.
One of the most important and anxiety-producing concerns among patients with lupus is whether it is safe to become pregnant. A pioneering study led by researchers at Hospital for Special Surgery has shown that most women can expect a good pregnancy outcome if their lupus is inactive and they are free of certain risk factors.
› Verified 4 days ago
| Entity Name | White River Health System Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568442127 PECOS PAC ID: 0143134270 Enrollment ID: O20060221000012 |
News Archive
Researchers at the Mayo Clinic campus in Florida have found a clue as to how some people develop a form of dementia that affects the brain areas associated with personality, behavior, and language.
That micro-organisms have a great capacity to vary their surface structure is well known. It is one of the reasons why it is so difficult to develop vaccines against HIV and malaria, and why new influenza vaccines have to be produced every year. But it seems that these micro-organisms are also able to completely avoid activating a strong immune response in the person attacked.
Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development of first-in-class, targeted oncolytic products for cancer, today reported positive interim data from a pilot trial using JX-594 followed by sorafenib (Nexavar®) to treat liver cancer patients. The data were presented today at the Fourth Annual International Liver Cancer Association Conference in Montreal, Canada.
Acorda Therapeutics, Inc. today announced that four new analyses of clinical trial data on AMPYRA™ (dalfampridine) Extended Release Tablets 10 mg are being presented at the 62nd American Academy of Neurology Annual meeting.
One of the most important and anxiety-producing concerns among patients with lupus is whether it is safe to become pregnant. A pioneering study led by researchers at Hospital for Special Surgery has shown that most women can expect a good pregnancy outcome if their lupus is inactive and they are free of certain risk factors.
› Verified 4 days ago
| Entity Name | White River Health System Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871609743 PECOS PAC ID: 0143134270 Enrollment ID: O20070223000663 |
News Archive
Researchers at the Mayo Clinic campus in Florida have found a clue as to how some people develop a form of dementia that affects the brain areas associated with personality, behavior, and language.
That micro-organisms have a great capacity to vary their surface structure is well known. It is one of the reasons why it is so difficult to develop vaccines against HIV and malaria, and why new influenza vaccines have to be produced every year. But it seems that these micro-organisms are also able to completely avoid activating a strong immune response in the person attacked.
Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development of first-in-class, targeted oncolytic products for cancer, today reported positive interim data from a pilot trial using JX-594 followed by sorafenib (Nexavar®) to treat liver cancer patients. The data were presented today at the Fourth Annual International Liver Cancer Association Conference in Montreal, Canada.
Acorda Therapeutics, Inc. today announced that four new analyses of clinical trial data on AMPYRA™ (dalfampridine) Extended Release Tablets 10 mg are being presented at the 62nd American Academy of Neurology Annual meeting.
One of the most important and anxiety-producing concerns among patients with lupus is whether it is safe to become pregnant. A pioneering study led by researchers at Hospital for Special Surgery has shown that most women can expect a good pregnancy outcome if their lupus is inactive and they are free of certain risk factors.
› Verified 4 days ago
| Entity Name | White River Health System Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477523348 PECOS PAC ID: 0143134270 Enrollment ID: O20110510000339 |
News Archive
Researchers at the Mayo Clinic campus in Florida have found a clue as to how some people develop a form of dementia that affects the brain areas associated with personality, behavior, and language.
That micro-organisms have a great capacity to vary their surface structure is well known. It is one of the reasons why it is so difficult to develop vaccines against HIV and malaria, and why new influenza vaccines have to be produced every year. But it seems that these micro-organisms are also able to completely avoid activating a strong immune response in the person attacked.
Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development of first-in-class, targeted oncolytic products for cancer, today reported positive interim data from a pilot trial using JX-594 followed by sorafenib (Nexavar®) to treat liver cancer patients. The data were presented today at the Fourth Annual International Liver Cancer Association Conference in Montreal, Canada.
Acorda Therapeutics, Inc. today announced that four new analyses of clinical trial data on AMPYRA™ (dalfampridine) Extended Release Tablets 10 mg are being presented at the 62nd American Academy of Neurology Annual meeting.
One of the most important and anxiety-producing concerns among patients with lupus is whether it is safe to become pregnant. A pioneering study led by researchers at Hospital for Special Surgery has shown that most women can expect a good pregnancy outcome if their lupus is inactive and they are free of certain risk factors.
› Verified 4 days ago
| Entity Name | White River Health System Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962878207 PECOS PAC ID: 0143134270 Enrollment ID: O20160318001395 |
News Archive
Researchers at the Mayo Clinic campus in Florida have found a clue as to how some people develop a form of dementia that affects the brain areas associated with personality, behavior, and language.
That micro-organisms have a great capacity to vary their surface structure is well known. It is one of the reasons why it is so difficult to develop vaccines against HIV and malaria, and why new influenza vaccines have to be produced every year. But it seems that these micro-organisms are also able to completely avoid activating a strong immune response in the person attacked.
Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development of first-in-class, targeted oncolytic products for cancer, today reported positive interim data from a pilot trial using JX-594 followed by sorafenib (Nexavar®) to treat liver cancer patients. The data were presented today at the Fourth Annual International Liver Cancer Association Conference in Montreal, Canada.
Acorda Therapeutics, Inc. today announced that four new analyses of clinical trial data on AMPYRA™ (dalfampridine) Extended Release Tablets 10 mg are being presented at the 62nd American Academy of Neurology Annual meeting.
One of the most important and anxiety-producing concerns among patients with lupus is whether it is safe to become pregnant. A pioneering study led by researchers at Hospital for Special Surgery has shown that most women can expect a good pregnancy outcome if their lupus is inactive and they are free of certain risk factors.
› Verified 4 days ago
| Entity Name | White River Health System Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104275486 PECOS PAC ID: 0143134270 Enrollment ID: O20170119000552 |
News Archive
Researchers at the Mayo Clinic campus in Florida have found a clue as to how some people develop a form of dementia that affects the brain areas associated with personality, behavior, and language.
That micro-organisms have a great capacity to vary their surface structure is well known. It is one of the reasons why it is so difficult to develop vaccines against HIV and malaria, and why new influenza vaccines have to be produced every year. But it seems that these micro-organisms are also able to completely avoid activating a strong immune response in the person attacked.
Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development of first-in-class, targeted oncolytic products for cancer, today reported positive interim data from a pilot trial using JX-594 followed by sorafenib (Nexavar®) to treat liver cancer patients. The data were presented today at the Fourth Annual International Liver Cancer Association Conference in Montreal, Canada.
Acorda Therapeutics, Inc. today announced that four new analyses of clinical trial data on AMPYRA™ (dalfampridine) Extended Release Tablets 10 mg are being presented at the 62nd American Academy of Neurology Annual meeting.
One of the most important and anxiety-producing concerns among patients with lupus is whether it is safe to become pregnant. A pioneering study led by researchers at Hospital for Special Surgery has shown that most women can expect a good pregnancy outcome if their lupus is inactive and they are free of certain risk factors.
› Verified 4 days ago
| Entity Name | White River Health System Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013451186 PECOS PAC ID: 0143134270 Enrollment ID: O20170125002953 |
News Archive
Researchers at the Mayo Clinic campus in Florida have found a clue as to how some people develop a form of dementia that affects the brain areas associated with personality, behavior, and language.
That micro-organisms have a great capacity to vary their surface structure is well known. It is one of the reasons why it is so difficult to develop vaccines against HIV and malaria, and why new influenza vaccines have to be produced every year. But it seems that these micro-organisms are also able to completely avoid activating a strong immune response in the person attacked.
Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development of first-in-class, targeted oncolytic products for cancer, today reported positive interim data from a pilot trial using JX-594 followed by sorafenib (Nexavar®) to treat liver cancer patients. The data were presented today at the Fourth Annual International Liver Cancer Association Conference in Montreal, Canada.
Acorda Therapeutics, Inc. today announced that four new analyses of clinical trial data on AMPYRA™ (dalfampridine) Extended Release Tablets 10 mg are being presented at the 62nd American Academy of Neurology Annual meeting.
One of the most important and anxiety-producing concerns among patients with lupus is whether it is safe to become pregnant. A pioneering study led by researchers at Hospital for Special Surgery has shown that most women can expect a good pregnancy outcome if their lupus is inactive and they are free of certain risk factors.
› Verified 4 days ago
| Entity Name | White River Health System Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154770436 PECOS PAC ID: 0143134270 Enrollment ID: O20170216001323 |
News Archive
Researchers at the Mayo Clinic campus in Florida have found a clue as to how some people develop a form of dementia that affects the brain areas associated with personality, behavior, and language.
That micro-organisms have a great capacity to vary their surface structure is well known. It is one of the reasons why it is so difficult to develop vaccines against HIV and malaria, and why new influenza vaccines have to be produced every year. But it seems that these micro-organisms are also able to completely avoid activating a strong immune response in the person attacked.
Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development of first-in-class, targeted oncolytic products for cancer, today reported positive interim data from a pilot trial using JX-594 followed by sorafenib (Nexavar®) to treat liver cancer patients. The data were presented today at the Fourth Annual International Liver Cancer Association Conference in Montreal, Canada.
Acorda Therapeutics, Inc. today announced that four new analyses of clinical trial data on AMPYRA™ (dalfampridine) Extended Release Tablets 10 mg are being presented at the 62nd American Academy of Neurology Annual meeting.
One of the most important and anxiety-producing concerns among patients with lupus is whether it is safe to become pregnant. A pioneering study led by researchers at Hospital for Special Surgery has shown that most women can expect a good pregnancy outcome if their lupus is inactive and they are free of certain risk factors.
› Verified 4 days ago
| Entity Name | White River Health System Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043742596 PECOS PAC ID: 0143134270 Enrollment ID: O20170607000110 |
News Archive
Researchers at the Mayo Clinic campus in Florida have found a clue as to how some people develop a form of dementia that affects the brain areas associated with personality, behavior, and language.
That micro-organisms have a great capacity to vary their surface structure is well known. It is one of the reasons why it is so difficult to develop vaccines against HIV and malaria, and why new influenza vaccines have to be produced every year. But it seems that these micro-organisms are also able to completely avoid activating a strong immune response in the person attacked.
Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development of first-in-class, targeted oncolytic products for cancer, today reported positive interim data from a pilot trial using JX-594 followed by sorafenib (Nexavar®) to treat liver cancer patients. The data were presented today at the Fourth Annual International Liver Cancer Association Conference in Montreal, Canada.
Acorda Therapeutics, Inc. today announced that four new analyses of clinical trial data on AMPYRA™ (dalfampridine) Extended Release Tablets 10 mg are being presented at the 62nd American Academy of Neurology Annual meeting.
One of the most important and anxiety-producing concerns among patients with lupus is whether it is safe to become pregnant. A pioneering study led by researchers at Hospital for Special Surgery has shown that most women can expect a good pregnancy outcome if their lupus is inactive and they are free of certain risk factors.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Robin Kerr, APN 16 Hospital Cir Ste A, Batesville, AR 72501-7343 Ph: (870) 262-5545 | Robin Kerr, APN 1215 Sidney St Ste 300, Batesville, AR 72501-7201 Ph: (870) 793-1126 |
News Archive
Researchers at the Mayo Clinic campus in Florida have found a clue as to how some people develop a form of dementia that affects the brain areas associated with personality, behavior, and language.
That micro-organisms have a great capacity to vary their surface structure is well known. It is one of the reasons why it is so difficult to develop vaccines against HIV and malaria, and why new influenza vaccines have to be produced every year. But it seems that these micro-organisms are also able to completely avoid activating a strong immune response in the person attacked.
Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development of first-in-class, targeted oncolytic products for cancer, today reported positive interim data from a pilot trial using JX-594 followed by sorafenib (Nexavar®) to treat liver cancer patients. The data were presented today at the Fourth Annual International Liver Cancer Association Conference in Montreal, Canada.
Acorda Therapeutics, Inc. today announced that four new analyses of clinical trial data on AMPYRA™ (dalfampridine) Extended Release Tablets 10 mg are being presented at the 62nd American Academy of Neurology Annual meeting.
One of the most important and anxiety-producing concerns among patients with lupus is whether it is safe to become pregnant. A pioneering study led by researchers at Hospital for Special Surgery has shown that most women can expect a good pregnancy outcome if their lupus is inactive and they are free of certain risk factors.
› Verified 4 days ago
Mr. Leroy Maupin Jr., APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 407 Virginia Dr, Batesville, AR 72501 Phone: 870-793-4200 Fax: 870-698-1353 | |
Angela Burleson, MS, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1215 Sidney St Ste 202, Batesville, AR 72501 Phone: 870-262-2000 | |
Rachel Jeannette Johnson, Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 905 20th St Ste B, Batesville, AR 72501 Phone: 870-569-4942 Fax: 870-569-4943 | |
Mrs. Michelle Lee Hagen, ACNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1710 Harrison St, Batesville, AR 72501 Phone: 870-262-1200 Fax: 870-262-6199 | |
Cynthia Elaine Jackson, APN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 3443 Harrison St, Batesville, AR 72501 Phone: 870-698-1635 Fax: 870-612-3389 | |
Brandy M Moore, APRN Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 255 Virginia Dr, Batesville, AR 72501 Phone: 870-793-4300 |